A novel approach for enriching cancer stem cells from the human SW-13 adrenocortical carcinoma cell line. 2014

Wenqing Zeng, and Xiaozhou Chen, and Yan Ma, and Zhenxing Huang, and Yuan Qin, and Fengping Wu, and Lili Wu, and Xinghuan Liang, and Yingfen Qin, and Jia Zhou, and Decheng Lu, and Xiaocong Kuang, and Qingdi Quentin Li, and Zuojie Luo
National Institutes of Health, Bethesda, MD 20892, U.S.A. E-mail: liquenti@mail.nih.gov or Dr. Zuojie Luo, Department of Endocrinology, First Hospital of Guangxi Medical University, Nanning 530021, China. zluo888@163.com.

The present study was undertaken to develop a new method for enriching cancer stem cells (CSCs) from the human adrenal cortical carcinoma (ACC) cell line SW-13. Given that the existence of CSCs in ACC causes resistance to conventional chemotherapies, treatment with cyclophosphamide was used for in vivo selection of CSCs in a BALB/c nude mouse tumor xenograft model established using the ACC cell line SW-13. The characteristics of CSCs in three generations of tumor xenografts were assessed for single-cell colony formation, flat colony formation, and cell sphere formation in serum-free suspension culture. The formation rates of single-cell colonies, flat colonies, and cell spheres were significantly higher for tumor xenograft cells treated with cyclophosphamide than for untreated engrafted tumor cells. Flow cytometry to examine expression of the CSC markers C-X-C chemokine receptor type-4 (CXCR4; CD184) and ATP-binding cassette sub-family G member-2 (ABCG2; CDw338) revealed markedly higher levels of CXCR4 and ABCG2 in cyclophosphamide-treated xenograft tumor cells compared to untreated tumor cells. Together, these results indicate that cyclophosphamide treatment of tumor xenograft cells caused enrichment of CSCs with a strong capability for self-renewal and proliferation. In this method, the administration of cyclophosphamide selectively kills cancer cells without toxicity to CSCs and thereby provides a practical approach for achieving the enrichment of CSCs in ACC.

UI MeSH Term Description Entries
D008297 Male Males
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D002469 Cell Separation Techniques for separating distinct populations of cells. Cell Isolation,Cell Segregation,Isolation, Cell,Cell Isolations,Cell Segregations,Cell Separations,Isolations, Cell,Segregation, Cell,Segregations, Cell,Separation, Cell,Separations, Cell
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000070997 ATP Binding Cassette Transporter, Subfamily G, Member 2 ATP-binding cassette transporter, sub-family G protein that functions as a high capacity UREA exporter, transporter of STEROLS, and in the absorption and efflux of many drugs. Its efflux activity for ANTINEOPLASTIC AGENTS contributes to DRUG RESISTANCE. It functions as a homodimer and is expressed by cells in a variety of organs, as well as by NEOPLASTIC STEM CELLS. ABCG2 Protein,ABCG2 Transporter,ATP Binding Cassette Transporter, Sub-Family G, Member 2,CD338 Antigen
D000306 Adrenal Cortex Neoplasms Tumors or cancers of the ADRENAL CORTEX. Adrenocortical Cancer,Cancer of Adrenal Cortex,Adrenal Cortex Cancer,Cancer of the Adrenal Cortex,Neoplasms, Adrenal Cortex,Adrenal Cortex Cancers,Adrenal Cortex Neoplasm,Adrenocortical Cancers,Cancer, Adrenal Cortex,Cancer, Adrenocortical,Cancers, Adrenal Cortex,Cancers, Adrenocortical,Neoplasm, Adrenal Cortex

Related Publications

Wenqing Zeng, and Xiaozhou Chen, and Yan Ma, and Zhenxing Huang, and Yuan Qin, and Fengping Wu, and Lili Wu, and Xinghuan Liang, and Yingfen Qin, and Jia Zhou, and Decheng Lu, and Xiaocong Kuang, and Qingdi Quentin Li, and Zuojie Luo
November 2000, Journal of cardiovascular pharmacology,
Wenqing Zeng, and Xiaozhou Chen, and Yan Ma, and Zhenxing Huang, and Yuan Qin, and Fengping Wu, and Lili Wu, and Xinghuan Liang, and Yingfen Qin, and Jia Zhou, and Decheng Lu, and Xiaocong Kuang, and Qingdi Quentin Li, and Zuojie Luo
March 2006, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
Wenqing Zeng, and Xiaozhou Chen, and Yan Ma, and Zhenxing Huang, and Yuan Qin, and Fengping Wu, and Lili Wu, and Xinghuan Liang, and Yingfen Qin, and Jia Zhou, and Decheng Lu, and Xiaocong Kuang, and Qingdi Quentin Li, and Zuojie Luo
February 1988, Endocrinologia japonica,
Wenqing Zeng, and Xiaozhou Chen, and Yan Ma, and Zhenxing Huang, and Yuan Qin, and Fengping Wu, and Lili Wu, and Xinghuan Liang, and Yingfen Qin, and Jia Zhou, and Decheng Lu, and Xiaocong Kuang, and Qingdi Quentin Li, and Zuojie Luo
March 2005, International journal of molecular medicine,
Wenqing Zeng, and Xiaozhou Chen, and Yan Ma, and Zhenxing Huang, and Yuan Qin, and Fengping Wu, and Lili Wu, and Xinghuan Liang, and Yingfen Qin, and Jia Zhou, and Decheng Lu, and Xiaocong Kuang, and Qingdi Quentin Li, and Zuojie Luo
August 2009, Cancer letters,
Wenqing Zeng, and Xiaozhou Chen, and Yan Ma, and Zhenxing Huang, and Yuan Qin, and Fengping Wu, and Lili Wu, and Xinghuan Liang, and Yingfen Qin, and Jia Zhou, and Decheng Lu, and Xiaocong Kuang, and Qingdi Quentin Li, and Zuojie Luo
November 2010, Cellular and molecular life sciences : CMLS,
Wenqing Zeng, and Xiaozhou Chen, and Yan Ma, and Zhenxing Huang, and Yuan Qin, and Fengping Wu, and Lili Wu, and Xinghuan Liang, and Yingfen Qin, and Jia Zhou, and Decheng Lu, and Xiaocong Kuang, and Qingdi Quentin Li, and Zuojie Luo
December 2015, Oncology reports,
Wenqing Zeng, and Xiaozhou Chen, and Yan Ma, and Zhenxing Huang, and Yuan Qin, and Fengping Wu, and Lili Wu, and Xinghuan Liang, and Yingfen Qin, and Jia Zhou, and Decheng Lu, and Xiaocong Kuang, and Qingdi Quentin Li, and Zuojie Luo
January 2009, Neoplasma,
Wenqing Zeng, and Xiaozhou Chen, and Yan Ma, and Zhenxing Huang, and Yuan Qin, and Fengping Wu, and Lili Wu, and Xinghuan Liang, and Yingfen Qin, and Jia Zhou, and Decheng Lu, and Xiaocong Kuang, and Qingdi Quentin Li, and Zuojie Luo
March 2008, Endocrinology,
Wenqing Zeng, and Xiaozhou Chen, and Yan Ma, and Zhenxing Huang, and Yuan Qin, and Fengping Wu, and Lili Wu, and Xinghuan Liang, and Yingfen Qin, and Jia Zhou, and Decheng Lu, and Xiaocong Kuang, and Qingdi Quentin Li, and Zuojie Luo
August 1973, Journal of the National Cancer Institute,
Copied contents to your clipboard!